Change of Adviser

    RNS Number : 1826I
  Lipoxen PLC
  14 November 2008
   
    Lipoxen PLC
    Change of NOMAD

     13 November, 2008   Lipoxen announces that in accordance with AIM Rule 17, the Company's nominated adviser and broker is Teathers, a
division of Straumur-Burdaras Investment Bank hf., of:

    Berkeley Square House,
Third Floor, 
Berkeley Square,
London
W1J 6BU
    Enquiries:

 Lipoxen PLC                                                    
 M. Scott Maguire, Chief Executive Officer  [phone] 
                                                                
 Teathers Limited (nominated adviser)                           
 Shaun Dobson / Claes Sp?                    [phone]
                                                                
 Citigate Dewe Rogerson                      [phone]
 David Dible / Heather Keohane                                  

    Notes to Editors
    Lipoxen PLC (AIM:LPX) is a biopharmaceutical company specializing in the development of high value differentiated biologicals, vaccines
and oncology drugs. Products currently under development include improved formulations of important biologicals such as erythropoietin
(EPO), G-CSF, insulin and Interferon-alpha. Lipoxen has two products in clinical development SuliXen, a long acting insulin and long-acting
EPO. These novel products, which are based on Lipoxen's proprietary PolyXen® technology, each address markets in excess of US$1 billion. 

    Lipoxen's technology is designed to improve the stability, biological half-life and immunologic characteristics of therapeutic proteins
naturally. Lipoxen has two further naturally-derived proprietary delivery technologies, ImuXen® and a related liposomal technology for the
formulation of cytotoxic oncology drugs, which are being developed to enhance the efficacy and safety of various vaccines such as a
multivalent Hepatitis B-E and pneumococcal vaccines, as well as a number of anti-cancer agents like paclitaxel. The Company's proprietary
delivery technologies are attracting significant interest and Lipoxen is currently co-developing products with the Serum Institute of India
Limited (one of the world's leading vaccine companies, India's largest biotech company and a major shareholder in Lipoxen) and has license
agreements in place with Baxter International and InterVet, a leading animal health company.

    Lipoxen was admitted to trading on the AIM Market of the London Stock Exchange in January 2006.


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
APPGUGQCGUPRGUC